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ABSTRACT

The presently-disclosed subject matter provides methods for
preventing ischemia in a cell, treating ischemia in a subject,
and preventing an infarction in a subject that utilize a5~1
integrin inhibitor. In some instances, a5 ~ 1 integrin inhibitor
is administered to a subject prior to, during, or after the onset
of ischemia to treat the ischemia and/or prevent infarction. In
some instances the present methods prevent the occurrence of
an infarction. In some instances the present methods restores
perfusion to organs and tissues.
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COMPOSITIONS AND METHODS FOR
TREATING ISCHEMIA

DESCRIPTION OF THE DRAWINGS

RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional
Patent Application No. 61/938,621, filed Feb. 11,2014, the
entire disclosure of which is hereby incorporated by reference.
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GOVERNMENT INTEREST
This invention was made with government support under
Grant No. 2R~1NS065842-08 the awarded by the National
Institutes of Health. The government has certain rights in the
invention.
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TECHNICAL FIELD
The presently-disclosed subject matter relates to the treatment of ischemia, including cerebral ischemia and stroke. In
particular, embodiments of the presently-disclosed subject
matter relate to methods for preventing and/or treating
ischemia and potential infarction that utilize an a5 ~ 1 integrin
inhibitor.

20

25

INTRODUCTION
Tissues deprived of blood and oxygen undergo ischemic
necrosis or infarction with possible irreversible organ damage. Cerebral ischemia results from decreased blood and oxygen flow implicating one or more of the blood vessels of the
brain. In cerebral ischemia, the individual suffers a stroke
with sudden development of a focal neurologic deficit and, in
most cases, some degree of brain damage. The decreased
blood flow may be due to, for example, an occlusion such as
a thrombus or embolus, vessel rupture, sudden fall in blood
pressure, change in the vessel lumen diameter due to atherosclerosis, trauma, aneurysm, developmental malformation,
altered permeability of the vessel wall or increased viscosity
or other quality of the blood. Decreased blood flow may also
be due to failure of the systemic circulation and severe prolongedhypotension. Ischemic necrosis of the spinal cord may
result in sensory or motor symptoms or both that can be
referred to cervical, thoracic or lumbar levels of the spine.
Current treatments for ischemia encompass behavioral
changes, drug therapy, and/or surgical intervention. Drugs are
frequently preferred before resorting to invasive procedures
and to provide more immediate relief than long-term behavioral changes. However, current drugs are limited in their
effectiveness in preventing infarction.
Similarly, stroke is the fourth leading cause of death in the
U.S., and approximately 87% of stroke patients are ischemic,
resulting from a lack of blood flow to a part of the brain.
Current standard of care for ischemic stroke is rapid reopening of the occluded brain blood vessel with tissue plasminogen activator (t-PA). Unfortunately, t-PA is limited to a brief
window of 4.5 hours within symptom onset contributing,
along with other factors, to the exclusion of many patients.
Furthermore, results from large t-PA trials have been mixed,
showing improving recanalization rates, but no overwhelming improvements in outcome.
Thus, there is a need for a therapeutic agent which can be
useful in treating ischemia as well as associated infarction and
cell death.
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Illustrative aspects of embodiments of the present invention will be described in detail with reference to the following
figures wherein:
FIG. lA includes images of brains where carbon black ink
was injected into the cerebral vasculature showing the left
hemisphere, where the shaded region indicates the territory of
the middle cerebral artery (MCA).
FIG.lB includes a plot showing the quantification ofMCA
territory area in control and a5 KO (knockout) mice brains
shown in FIG. lA. N=6. Bars=SD.
FIG. 2A includes images oflaser speckle doppler flow of
WT (wild type) and a5 integrin KO mice at just prior and
immediately following (L)eft MCAo.
FIG. 2B includes a plot showing levels of perfusion for the
samples WT and a5 integrin KO mice at just prior and immediately following (L)eft MCAo, where the data are obtained
from the respective circled areas shown in FIG. 2A (N=3
animals per group, *P<0.05).
FIG. 3A includes images showing TTC in WT and a5
integrin KO mice brains 3 days after MCAo (PSD 3), where
arrows indicate TTC negative areas.
FIG. 3B includes a plot showing the quantification of mean
infarct volumes of the mice brains shown in FIG. 3A (N=18
per group per PSD, 3 separate experiments, *P<O.OOl).
FIG. 4 includes images of a cresyl violet stain of strokeaffected and contralateral brain areas showing a significant
neuronal cell dropout and pyknotic appearing neurons in WT
mice but no appreciable cell dropout and relatively few
pyknotic appearing neurons in a5 integrin KO mice. Scale
bar=50 fllll·
FIG. 5 includes images of TUNEL stains with DAPI
nuclear counterstains of stroke-affected brain areas showing
substantial and increased apoptosis in WT mice from PSD 1-3
but minimal apoptosis in a5 integrin KO mice (n=3). Scale
bar is 50 f.tm.
FIG. 6 includes images showing IgG (DAB stain) immunohistochemistry of stroked brain tissue on PSD 1 and 3 that
were counterstained with hematoxylin. N=6. Scale bar is 50
f.tm.
FIG. 7A includes images ofPSD3 TTC stained brain sections showing WT mice treated with intravenous PBS (Control) or ATN -161 (1 mg/kg) on PSD 1.
FIG. 7B includes a plot showing the quantification of mean
infarct volume of the mice samples shown in FIG. 7A (expressed as a percent of control normalized to 100%). N=12,
*P<0.05.
FIG. 7C includes images of TUNEL stain with DAPI
nuclear counterstain showing stroke-affected brain areas on
PSD3 as labeled, and demonstrating increased apoptosis in
PBS treated versus ATN -161 treated mice. Scale bar is 50 f.tm.
FIG. SA includes a schematic showing that activation of
a5~1 integrin by fibronectin increases inhibition of PKA,
lowers levels of phosphorylation-mediated activation ofGDI,
increases levels of dissociated and active RhoA, increases
activation of ROCK!, causes actin stress fiber rearrangement
and phosphorylation of claudin-5 at position T207, creates a
less tight junction integrity and increases BBB permeability,
and subsequently leads to endothelial cell activation and
increases a5~1 integrin expression.
FIG. SB includes a schematic showing that inhibition or
absence of the a5~1 integrin prevents inhibition of PKA,
increases phosphorylation-mediated activation of GDI, and
creates no dissociation of RhoA as well as reduces ROCK!
activation, rearranges F -actin, and phosphorylizes claudin-5.
This increases tight junction connections between endothe-
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lial cells decreases permeability and cellular activation, and
prevents increase in aS~ 1 expression and endothelial cell
activation.
FIG. 9 includes a plot of post-OGD FITC-dextran permeability measurements across the monolayer of confluent (6
days) WT mouse brain endothelial cells exposed to OGD for
8 hours+/-ATN-161 (10 f.LM added 4 hours after OGD) and
then returned to normoxic and normoglycemic conditions.
Results shown as a percentage of pre-OGD FITC-dextran
fluorescence in untreated WT cells, normalized to 100%
(dashed line). **p<O.Ol. N=4.
FIG. lOA includes a Western blot for aS integrin from WT
mouse brain endothelial cells+/-ATN-161 before and after
OGD as labeled.
FIG. lOB includes a plot showing the quantification (mean
values) of aS western blots (as in FIG. lOA) normalized to
Ponceau S. total protein stain and expressed as a % change
from PBS treated pre-OGD cells. N=3. *p<O.OS.
FIG. llA includes a claudin-S western blot ofbrain endothelial cells after OGD that were treated as labeled.
FIG. llB includes plot showing the quantification of claudin-S expression normalized to Ponceau S total protein stain
for the samples show in FIG. llA.
FIG. llC includes images showing claudin-S immunocytochemistry of WT mouse brain endothelial cells either just
prior to (control) or 24 hours after OGD treated as labeled.
Scale bar is S f.Lm.

degree of reduction or elimination of ischemia. Likewise, the
term "preventing" does not imply that infarction due to
ischemia is eliminated. Instead, the term "preventing" refers
to reducing ischemia as well as side effects thereof, including
potentially infarction, by about 1, 2, 3, 4, S, 6, 7, 8, 9, 10, 11,
12, 13,14, 1S, 16, 17, 18,19,20,21,22,23,24,2S,26,27,28,
29,30,31,32,33,34,3S,36,37,38,39,40,41,42,43,44,4S,

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and
other embodiments, will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and
particularly the specific details of the described exemplary
embodiments, is provided primarily for clearness of understanding, and no unnecessary limitations are to be understood
therefrom.
The presently disclosed subject matter is directed to preventing and/or treating ischemia with methods that involve
use of an aS~1 integrin inhibitor. As is known in the art,
ischemia can lead to infarction in a subject. Therefore, the
presently-disclosed subject matter further relates to methods
for preventing and/or treating an infarction in a subject, and
such methods involve the use of an aS~ 1 integrin inhibitor.
In some embodiments, a method is provided for preventing
ischemia in a cell, wherein the ischemia may be caused by one
or more ischemic events. In some embodiment the method
includes contacting the cell with an aS~1 integrin inhibitor.
The term "contacting" as used herein refers to any means by
which an aS~ 1 integrin inhibitor brought into sufficient proximity and/or in direct contact with a cell such that the cell is
capable of receiving the aS~ 1 integrin inhibitor. For instance,
in some embodiments contact refers to coating a cell with an
aS~ 1 integrin inhibitor. In other embodiments contact refers
to culturing a cell in a solution that includes an aS~ 1 integrin
inhibitor. In other embodiments the cell is within a subject,
and contact refers to administering an aS~ 1 integrin inhibitor
to the subject such that a cell within the subject is capable of
receiving an aS~1 integrin inhibitor.
The term "preventing" as used herein refers to the characteristic of reducing or eliminating ischemia as well as the side
effects associated with ischemia, which can include infarction. The term "preventing" does not imply a particular

46,47,48,49,SO,S1,S2,S3,S4,SS,S6,S7,S8,S9,60,61,62,
63,64,6S,66,67,68,69,70, 71, 72, 73, 74,7S, 76, 77, 78, 79,
80,81,82,83,84,8S,86,87,88,89,90,91,92,93,94,9S,96,
97, 98, 99, or 100% relative to a control that has not been
contacted or treated with an aS~ 1 integrin inhibitor.
Furthermore, the terms "inhibitor" and the like do not
necessarily refer to the ability to completely inactivate all
15 target biological activity in all cases. Rather, the skilled artisan will understand that the term "inhibitor" refers to a substance that can decrease biological activity of a target, such as
can occur with a ligand binding site of the target, or protein in
a biochemical pathway of the target is blocked, or when a
20 non-native complex with the target, or protein in a biochemical pathway of the target, is formed. Such decrease in biological activity can be determined relative to a control,
wherein an inhibitor is not administered and/or placed in
contact with the target. Accordingly, the term "aS~ 1 integrin
25 inhibitor" refers to substances that can decrease or eliminate
aS~ 1 integrin activity, optionally relative to a control that has
not been contacted with an aS~1 integrin inhibitor. In some
embodiments, a decrease in aS~1 integrin activity relative to
a control can be about a 1, 2, 3, 4, S, 6, 7, 8, 9, 10, 11, 12, 13,
30 14, 1S,16, 17, 18, 19,20,21,22,23,24,2S,26,27,28,29,30,
31,32,33,34,3S,36,37,38,39,40,41,42,43,44,4S,46,47,
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82,83,84,8S,86,87,88,89,90,91,92,93,94,9S,96,97,98,
99, or 100% decrease.
In some embodiments, the aS~1 integrin inhibitor is
selected from small molecule and a polypeptide.
As used herein, the term "polypeptide" means any polymer
comprising any of the 20 protein amino acids, regardless of its
size. Although "protein" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of these terms in the art
overlaps and varies. The term "polypeptide" as used herein
refers to peptides, polypeptides and proteins, nnless otherwise noted. As used herein, the terms "protein," "polypeptide," and "peptide" are used interchangeably herein when
referring to a gene product. Unless otherwise indicated, a
particular polypeptide also implicitly encompasses conservatively-substituted variants thereof.
As used herein, "small molecule" refers to a non-peptidic,
non-oligomeric organic compound either synthesized in the
laboratory or fonnd in nature. Small molecules, as used
herein, can refer to compounds that are "natural productlike," however, the term "small molecule" is not limited to
"natural product-like" compounds. Rather, a small molecule
is typically characterized in that it possesses one or more of
the following characteristics including having several carbon-carbon bonds, having multiple stereocenters, having
multiple functional groups, having at least two different types
of functional groups, and having a molecular weight of less
than 1SOO, although this characterization is not intended to be
limiting for the purposes of the disclosure.
In some embodiments the aS~1 integrin inhibitor is
selected from ATN-161, Ac-PhScN-NH 2 , CRRETAWAC
(SEQ. ID NO: 1) aS~1 integrin inhibitor peptide, and combinations thereof. ATN-161 is a peptide with the amino acid
sequence PHSCN that has been developed to inhibit aS~ 1
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integrin and has successfully completed Phase I and Phase II
clinical trials for recurrent intracranial malignant glioma.
Among other things, ATN-161 can be safely administered
intravenously, has a relatively short serum half-life (e.g., 3-5
h for some subjects) with high tissue distribution, and localizes to vasculature over-expressing activated, but not unactivated, a5~1 integrin. ATN-161, in addition to noncovalent
interaction with the a5 integrin subunit, can have a covalent
interaction with the ~1 and ~3 subunit of a5~1 and av~3
integrin.
Ac-PhScN-NH 2 is a modified version of ATN-161 in
which the covalent interaction is eliminated by replacing the
Hand C with D-stereoisomers. Ac-PhScN-NH 2 specifically
and noncovalently interacts with the a5 subunit of a5~1
integrin and is between 27,000 fold and 379,000 fold more
potent and specifically inhibits activated a5 ~ 1 integrin mediated processes.
In some embodiments the a5~ 1 integrin inhibitor includes
a CRRETAWAC a5~1 integrin inhibitor peptide. See, e.g.,
Koivunen E, Wang B, Ruoslahti E. Isolation of a highly
specific ligand for the alpha 5 beta 1 integrin from a phage
display library. J Cell Biol. 1994; 124(3):373-380. In some
embodiments the a5~1 integrin inhibitor is selected from an
a5~1 integrin antibody that inhibits the function of the a5~1
integrin inhibitor. Those of ordinary skill in the art will recognize antibodies for blocking the function of aS~ 1 integrin,
as well as such antibodies suited for use in particular subjects,
including human and non-human subjects.
Additionally, without being bound by theory or mechanism, relatively small peptides such as ATN-161, Ac-PhScN-NH2 and CRRETAWAC (SEQ ID NO: 1) a5~1 integrin inhibitor peptide may not be able to cross the intact
blood-brain barrier (BBB), like other small peptides cannot.
This characteristic can be advantageous for targeting circulation accessible activated brain endothelial cell a5~1 integrin
to potentially stabilize the BBB.
With respect to methods for preventing ischemia in a cell,
in some embodiments the cell is a brain cell. In other embodiments the cell is part of a particular tissue, and the method
includes preventing ischemia in the cell(s) of the tissue. In this
respect, the term "tissue" is used herein to refer to a population of cells, generally consisting of cells of the same kind that
perform the same or similar functions. The types of cells that
make the tissue are not limited. In some embodiments tissue
is part of a living organism, and in some embodiments tissue
is tissue excised from a living organism or artificial tissue. In
some embodiments tissue can be part of an organ, wherein the
term "organ" refers to a part of a subject which is composed
of several tissues and adapted to perform a specific function
or functions, such as the brain.
The presently-disclosed subject matter also relates to
methods for treating ischemia in a subject. In some embodiments the method comprises administering to the subject an
effective amount of an a5~1 integrin inhibitor. In some
embodiments the a5~1 integrin inhibitor is selected from
small molecule and a polypeptide. In some embodiments the
a5~1 integrin inhibitor is selected from ATN-161, Ac-PhScN-NH2 CRRETAWAC (SEQ ID NO: 1) a5~1 integrin
inhibitor peptide, and combinations thereof.
The term "administering" refers to any method of providing an a5~1 integrin inhibitor and/or pharmaceutical composition thereof to a subject. Such methods are well known to
those skilled in the art and include, but are not limited to, oral
administration, transdermal administration, nasal administration, intracerebral administration, and administration by
injuction, which itself can include intravenous administration, intra-arterial administration, intramuscular administra-

tion, subcutaneous administration, intravitreous administration, intracameral (into anterior chamber) administration, and
the like. Administration can be continuous or intermittent. In
various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or
condition (e.g., ischemia, infarction, etc.). In other instances
a preparation is administered prophylactically; that is, administered to prevent or treat a disease or condition that may
otherwise develop.
As used herein, the terms "effective amount" and "therapeutically effective amount" are used interchangeably and
mean a dosage sufficient to provide treatment. The exact
amount that is required will vary from subject to subject,
depending on the species, age, and general condition of the
subject, the particular carrier or adjuvant being used, mode of
administration, and the like. As such, the effective amount
will vary based on the particular circumstances, and an appropriate effective amount can be determined in a particular case
by one of ordinary skill in the art using only routine experimentation.
In some instances an effective amount is determined relative to the weight of a subject, and can be selected from
dosages of about 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5
mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11
mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg,
17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 21 mg/kg, 22
mg/kg, 23 mg/kg, 24 mg/kg, 25 mg/kg, 26 mg/kg, 27 mg/kg,
28 mg/kg, 29 mg/kg, 30 mg/kg, 31 mg/kg, 32 mg/kg, 33
mg/kg, 34 mg/kg, 35 mg/kg, 36 mg/kg, 37 mg/kg, 38 mg/kg,
39 mg/kg, 40 mg/kg, 41 mg/kg, 42 mg/kg, 43 mg/kg, 44
mg/kg, 45 mg/kg, 46 mg/kg, 47 mg/kg, 48 mg/kg, 49 mg/kg,
and 50 mg/kg.
The term "subject" is used herein to refer to a target of
administration, which optionally displays symptoms related
to a particular disease, pathological condition, disorder, or the
like. Thus, in some embodiments a subject refers to a target
that displays symptoms of ischemia and/or infarction. The
subject of the herein disclosed methods can include both
human and animal subjects. A subject can be, but is not
limited to, vertebrates, such as mammals, fish, birds, reptiles,
or amphibians. More specifically, the subject of the herein
disclosed methods can include, but is not limited to, a human,
non-human primate, cat, dog, deer, bison, horse, pig, rabbit,
dog, sheep, goat, cow, cat, guinea pig, or rodent. The term
does not denote a particular age or sex. Adult and newborn
subjects, as well as fetuses, whether male or female, are
intended to be covered. The term "subject" includes human
and veterinary subjects.
The terms "treat," "treatment," and the like refer to the
medical management of a subject with the intent to cure,
ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is,
treatment directed specifically toward the improvement of a
disease, pathological condition, or disorder, and also includes
causal treatment, that is, treatment directed toward removal of
the cause of the associated disease, pathological condition, or
disorder. In addition, this term includes palliative treatment,
that is, treatment designed for the relief of symptoms rather
than the curing of the disease, pathological condition, or
disorder; preventative (prophylatic) treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological
condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy
directed toward the improvement of the associated disease,
pathological condition, or disorder.
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In some methods for treating ischemia, the ischemia is
caused by a particular ischemic event. In some instances, the
ischemia is caused at least in part by an ischemic event
selected from cerebral ischemia, stroke, and a combination
thereof. In some embodiments the aS~1 integrin inhibitor is
administered one or more times during or after the onset of
ischemia and/or during or after an ischemic event. In this
respect, in some embodiments an aS~1 integrin inhibitor is
administered one or more times during or after the onset of
two or more distinct ischemic events, and therefore the
present methods are not limited to a single administration of
an aS~1 integrin inhibitor. In such embodiments, the aS~1
integrin inhibitor can optionally be administered about O.S, 1,
2, 3, 4, s, 6, 7, 8, 9, 10, 11, 12, 13, 14, 1S, 16, 17, 18, 19, 20,
21, 22, 23, 24, 2S, 26, 27, 28, 29, or 30 hours after the onset of
the ischemic.
As discussed above, treatment can be preventative (prophylactic) in some instances. Accordingly, in some embodiments of the presently-disclosed treatment methods, the
aS~1 integrin inhibitor is administered prior to the onset of
ischemia and/or prior to an ischemic event. In some embodiments the aS~1 integrin inhibitor is administered prior to
each of one or more separate onsets of ischemia and/or
ischemic events.
In some embodiments administration of an aS~ 1 integrin
inhibitor to a subject, prior to, during, and/or after the onset of
ischemia, can prevent (i.e., 1-100% reduction relative to control) the occurrence of infarction in the subject. Alternatively
or additionally, in some embodiments administration of an
aS~1 integrin inhibitor to a subject, prior to, during, and/or
after the onset of ischemia, can restore perfusion to tissues
and organs in the subject.
Further still, the presently-disclosed subject matter relates
to methods for preventing an infarction in a subject. In some
embodiments, a method for preventing an infarction in a
subject comprises administering an effective amount of an
aS~ 1 integrin inhibitor. In some embodiments the aS~ 1 integrin inhibitor is selected from small molecule and a polypeptide. In some embodiments the aS~1 integrin inhibitor is
selected from ATN-161, Ac-PhScN-NH 2 CRRETAWAC
(SEQ ID NO: 1) aS~ 1 integrin inhibitor peptide, and combinations thereof.
In some embodiments of methods for preventing an infraction in a subject, prior to administering an aS~1 integrin
inhibitor, the subject is first diagnosed and/or prognosed as
having ischemia. In some instances the subject can be diagnosed as having ischemia that has already led to an infarction
in the subject. Administration of an aS~1 integrin inhibitor
prior to an ischemic event, whether or not a subject has been
prognosed as being at risk for ischemia, could therefore serve
as a preventative treatment for ischemia, and potentially infarction.
The terms "diagnose" and the like as used herein refer to
methods by which the skilled artisan can estimate and even
determine whether or not a subject is suffering from a given
disease or condition, such as ischemia. Along with diagnosis,
clinical "prognosis" or "prognosticating" is also an area of
great concern and interest, and the terms "prognose" and the
like refer to act of determining the relative risk associated
with particular conditions in order to plan the most effective
therapy. If an accurate prognosis can be made, appropriate
therapy, and in some instances less severe therapy or more
effective therapy, for the subject can be chosen. For instance,
in some embodiments of the presently disclosed subject matter, a subject that is prognosed as having ischemia can have an
aS~1 integrin inhibitor administered in order to prevent the
potential ischemia from developing.

Those of ordinary skill in the art will recognize factors and
methods for diagnosing and/or prognosing a subject with
ischemia. Factors that can contribute to a diagnosis and/or
prognosis of ischemia in a subject include, but are not limited
to, hypercholesterolemia, electrocardiogram (EKG) changes
associated with a risk of or the presence of ischemia (e.g.,
peaked or inverted T-waves or ST segment elevations or
depression in an appropriate clinical context), sedentary lifestyles, angiographic evidence of partial coronary artery
obstruction, evidence of a cerebrovascular accident CVA, and
other clinical evidence of ischemia
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The presently-disclosed subject matter is further illustrated
by the following specific but non-limiting examples. The
examples may include compilations of data that are representative of data gathered at various times during the course of
development and experimentation related to the presentlydisclosed subject matter. Furthermore, some of the examples
described herein may be prophetic examples.
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This Example demonstrates that stroke-induced upregulation and activation of an aS~1 integrin allows systemically
administered domain V (DV) protein fragment of the brain
extracellular matrix proteoglycan perlecan to target a stroke
site. This Example therefore links the therapeutic effect of
DV to aS~ 1 integrin.
A transient middle cerebral artery occlusion (MCAo) was
performed in 3 month old male mice that had endothelial cell
selective knockdown of the aS integrin (referred to hereafter
as "aS integrin KO mice"). As the aS integrin subunit is
known to only heterodimerize with the ~ 1 integrin subunit,
this mouse is effectively deficient in endothelial cell aS~1
integrin. These mice were healthy, fertile, and had no spontaneous vascular or hematopoietic phenotypes, no alterations
in developmental vasculogenesis or angiogenesis, no differences in vascular extracellular matrix composition or structure, and no disparities in their subsets ofhematopoietic cells.
Furthermore, these mice localized more av~3 at the brain
endothelial cell surface in their focal adhesions, but exhibited
no increase in total av~S protein. Brain angiogenesis in the
face of chronic (14 days) hypoxia was significantly delayed in
these mice.
Relative to wild type (WT) littermates, analysis of the aS
integrin KO mice demonstrated no significant differences in
their cerebrovascular anatomy that could otherwise explain
any differences in experimental infarct size (FIGS. lA and
lB), no significant difference in brain microvascular density
as quantified by immunohistochemistry, and no significant
differences in blood gas parameters. During the stroke surgery, both aS integrin KO and WT littermates experienced
similar degradations in blood flow upon MCAo as measured
by laser speckle Doppler (Peri Cam PSI HR, Perimed, FIGS.
2A and 2B), reducing the likelihood that potential differences
in collateral circulation could account for differences in infarct size.
It was noted that the KO mice had little to no discernible
infarction, as measured by (TTC) and little sign of neuronal
injury (i.e., small, rounded, pyknotic appearing neurons by
cresyl violet stain) or apoptotic cell death from PSD1-3
(FIGS. 3 to 5). This degree of apparent resistance to ischemic
stroke injury is superior to other known genetically modified
mice. The lack of neuronal injury/death was associated with a
qPCR-measured decrease in the transcription of several pro-
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inflammatory cytokines (e.g. IL-l beta and TNFalpha were
0.33 fold and 0.34 fold, respectively, of PSD3 WT stroked
control levels, p<O.Ol, n=3) and an increase in several antiinflammatory cytokines (e.g., IL-4 and IL-10 were 131.87
fold and 2S.34 more than PSDl WT stroked control levels,
p<O.OOl, n=3) in ipsilateral ischemic brain. These observations collectively suggest that after MCAo, aS integrin KO
mice experience a combination ofless inflammation and little
to no neuronal death in ischemic areas.
In this regard, one of the more prominent ways in which
ischemic brain injury expands is via disruption of the bloodbrain barrier (BBB), allowing for cytotoxic and vasogenic
edema, infiltration of immune and inflammatory cells, and the
like. For this reason, limiting poststroke BBB disruption was
examined for potential therapeutic benefits. The BBB appears
to open and close repeatedly after transient ischemic stroke.
Typically, the hyperemia associated with reperfusion is associated with increased BBB opening, followed by a refractory
period of slight hypoperfusion and a closed BBB, which is
then followed by a biphasic period of BBB opening. Without
being bound by theory or mechanism, the earlier periods of
BBB opening may be due to increased endothelial transcytosis, while the final opening period, which typically occurs
between 18-96 hours after reperfusion, is associated with
increased paracellular permeability due to disruption of tight
junction (TJ) proteins such as claudin-S, vasogenic edema,
inflammatory cell infiltration, and the initiation of angiogenesis.
As discussed above, aS~l integrin is a mediator in the
angiogenic response, and is upregulated in stroke-affected
vasculature during the first 24 hours in the MCAo model.
Additionally, the difference in neuronal injury and inflammatory mediator transcription in the aS integrin KO mice was
evident as early as 24 hours post MCAo. Thus, the deletion of
this single endothelial cell integrin may cause such neuroprotection by preventing the final BBB opening by stabilizing TJ
proteins, thereby minimizing ischemic injury after transient
MCAo.

MCAo and assessed mean infarct volume and the extent of
TUNELpositive apoptosis onPSD3 (FIGS. 7A to 7C, N=12,
two separate experiments). ATN-161 treatment resulted in
little to no TTC detected infarct and minimal apoptosis, supporting the notion that pharmacologically targeting the aS~ 1
integrin in stroked subjects can be therapeutic. Additionally,
treatment withATN-161 did not alter animal vital signs upon
administration and was well tolerated, as indicated by a lack
of signs of illness such as fur ruffling, weight differences, and
the like.
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This Example describes procedures performed to further
characterize the effect of endothelial cell selective aS~ 1 integrin deletion on experimental ischemic stroke.
In addition to the results detailed in Example 1 for the aS
integrin KO mice (FIGS. 1 to 5), IgG immunohistochemistry
was performed to determine potential differences in poststrokeBBBpermeability onPSDl and3 (FIG. 6). IgGimmunoreactivity was abundant in all of the brains of stroked WT
mice at both PSDs, but was not detected in any of the aS
integrin KO mice brains (n=6). This supports the notion that
that the absence of endothelial cell aS integrin promotes
post-stroke BBB integrity.

45

50

Example 3
This Example describes procedures performed to characterize the potential of the aS~ 1 integrin as a therapeutic target
for ischemic stroke. As discussed above, aS integrin KO mice
suggest that the aS~ 1 integrin could represent an effective
stroke therapeutic target. In this Example, this therapeutic
quality will be investigated by determining whether inhibition of the more specific aS~l integrin in WT mice after
MCAo results in resistance to ischemic injury and improved
functional outcomes mirroring the results seen in stroked aS
integrin KO mice.
To determine the therapeutic potential of blocking the
aS~ 1 integrin after MCAo, 3 month old male WT mice were
treated withATN-161 or PBS vehicle control12 hours after
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This Example describes procedures performed to characterize the role of aS~l integrin in modulating blood-brain
barrier integrity and subsequent resistance to ischemic stroke.
Based on the results of the previous Examples that aS integrin
KO mice appear to resist post-stroke BBB breakdown after
transient MCAo, and that post-stroke claudin-S gene expression increases in these mice, it appears that suppression of
brain endothelial cell aS~ 1 integrin in an ischemia -affected
brain is neuroprotective, at least in part, by stabilization of the
post-stroke BBB via increased expression and function of
claudin-S.
Without being bound by theory or mechanism, claudin-S
stabilization, in addition to reducing paracellular permeability, could result in less cell surface expression of aS~l integrin, less endothelial cell activation, and less transcellular
permeability. Based on previous results, it appears that aS~ 1
is linked to protein kinase a (PKA), PKA to Ras homolog
family member A (RhoA) and barrier stability effects, and
RhoA to claudin-S function via Rho-associated coiled-coil
containing protein kinase 1 (ROCK!) mediated phosphorylation. Without being bound by theory or mechanism, a schematic for aS~ 1 mediation of tight junction (TJ) protein function and BBB permeability is summarized in FIGS. SA and
SB.
To determine whether inhibition of aS~l integrin with
ATN -161 in brain endothelial cells has any effect on their
permeability under baseline or stroke-like conditions (oxygen-glucose deprivation (OGD)-reperfusion) in vitro, FITC
dextran permeability experiments were performed with a
CS7BI6 WT brain endothelial cell line+/-ATN -161. While no
differences were noted in FITC dextran permeability in nonOGD exposed cells+/-ATN-161 treatment (data not shown),
ATN -161 blocked the OGD-mediated increase in endothelial
cell permeability to FITC-dextran (FIG. 9). As the 8 hour
OGD-24 hour reperfusion protocol did not cause significant
endothelial cell death or detachment (trypan blue cell exclusion assay, data not shown), the ATN-161 effect on permeability caunot be simply attributed to potential OGD cell
protection. This Example supports the notion that inhibition
of brain endothelial cell aS~ 1 integrin stabilizes brain endothelial cell permeability under stroke-like (OGD-reperfusion)
conditions.
Next, it was determined that ATN-161 could block the
OGD-induced increase in aS~l integrin expression in WT
brain endothelial cells (FIGS. lOA and lOB), supporting the
notion that inhibiting aS~ 1 integrin might help stabilize brain
endothelial cell permeability, in part, by preventing an
increase in aS~l integrin expression.
The studies also demonstrated that ATN -161 could prevent
the OGD-mediated decrease in claudin-S expression, as measured by western blot and immunocytochemistry, in mouse
brain endothelial cells, which could be inhibited by the PKA
specific inhibitor PKI (FIGS. llA to llC). It was noted that
Ac-PhScN-NH2 was more effective than ATN-161 in further increasing claudin-S levels above normoxic control levels.
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Next, to demonstrate whether absent brain endothelial cell
aS~ 1 integrin could affect claudin-S expression after stroke,
claudin-S qPCR was performed on PSD1 from the stroked
and sham cerebral hemispheres of aS integrin KO mice and
WT littermates. While sham claudin-S levels were identical
between the two genotypes, claudin-S gene expression
increased by 60% in stroked aS integrin KO mice relative to
stroked WT littermate controls, suggesting that endothelial
cell knockdown of aS~ 1 integrin positively effects claudin- S
gene expression after ischemic stroke.
While the terms used herein are believed to be well understood by one of ordinary skill in the art, definitions are set
forth herein to facilitate explanation of the presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the presentlydisclosed subject matter belongs. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presentlydisclosed subject matter, representative methods, devices,
and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "an inhibitor" includes a plurality of such inhibitors,
and so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and claims
are approximations that can vary depending upon the desired
properties sought to be obtained by the presently-disclosed
subject matter.
As used herein, the term "about," when referring to a value
or to an amount of mass, weight, time, volume, concentration
or percentage is meant to encompass variations of in some
embodiments ±20%, in some embodiments ±10%, in some
embodiments ±S%, in some embodiments ±1 %, in some
embodiments ±O.S%, and in some embodiments ±0.1% from
the specified amount, as such variations are appropriate to
perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10" is
also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, ifl 0 and
1S are disclosed, then 11, 12, 13, and 14 are also disclosed.
Throughout this document, various references are mentioned. All such references are incorporated herein by reference.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 1
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 9
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Synthesized

<400> SEQUENCE, 1
Cys Arg Arg Glu Thr Ala Trp Ala Cys
1

5

What is claimed is:
1. A method for treating ischemia in a subject, comprising:
administering to a subject in need thereof an effective amount
of a a5 ~ 1 integrin inhibitor thereby treating the ischemia,
wherein the ischemia is caused by an ischemic event
selected from cerebral ischemia and/or stroke,
and wherein the a5~1 integrin inhibitor is ATN-161 or
Ac-PhScN-NH 2 .
2. Themethodofclaim1, whereinthea5~1 integrininhibitor is administered during or after the onset of the ischemia.
3. Themethodofclaim1, whereinthea5~1 integrininhibitor is administered about 0.5 hours to about 30 hours after the
onset of the ischemia.
4. Themethodofclaim1, whereinthea5~1 integrininhibitor is administered prior to the onset of ischemia.
5. The method of claim 1, wherein the treatment prevents
the occurrence of an infarction.
6. The method of claim 1, wherein the treatment restores
perfusion to organs and tissues.
7. The method of claim 1, wherein the administering step
includes administering about 1 mg/kg to about 50 mg/kg of
the a5~1 integrin inhibitor.
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8. A method for preventing an infarction caused by a cerebral ischemia event in a subject, comprising: administering to
a subject in need thereof an effective amount of a a5~1
integrin inhibitor thereby preventing the infarction,
wherein prior to the step of administering the a5~ 1 integrin
inhibitor, the subject is diagnosed as having cerebral
ischemia,
and wherein the a5~1 integrin inhibitor is ATN-161 or
Ac-PhScN-NH 2 .
9. The method of claim 8, wherein the a5 ~ 1 integrin inhibitor is administered during, or after the cerebral ischemic
event.
10. The method of claim 9, wherein the a5~1 integrin
inhibitor is administered about 0.5 to about 30 hours after the
cerebral ischemic event.
11. The method of claim 8, wherein about 5% to about 95%
of infarction is prevented in the subject relative to a control
subject.
12. The method of claim 8, wherein the administering step
includes administering about 1 mg/kg to about 50 mg/kg of
the a59~1 integrin inhibitor.
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